Charco Neurotech
Charco Neurotech’s CUE1 wearable delivers individualised vibrotactile neuromodulation that helps thousands of people with Parkinson’s move more freely and live better, without surgery or drugs.
About
Charco Neurotech is a Cambridge-based medical-technology spin-out from Imperial College London, developing non-invasive neuromodulation therapies for people with Parkinson’s.
Its flagship wearable, CUE1 / CUE1+, sits discreetly on the sternum and delivers pulsed cueing and high-frequency vibrotactile stimulation to the peripheral nerves, easing motor symptoms such as slowness, stiffness, rigidity and freezing of gait. In pilot testing, users improved their MDS-UPDRS motor scores by an average of 7.8 points—clinically significant relief that more than 3,000 people now experience every day. The companion app lets users customise stimulation, set medication reminders and track symptoms, turning CUE1 into a personalised, data-rich therapy.
Charco Neurotech
Founded in 2019, the multi-award-winning team of designers, engineers and clinicians is driven by a single mission: to improve quality of life for the 10 million people living with Parkinson’s worldwide.
